レーバー遺伝性視神経症治療の世界市場レポート 2025年

レーバー遺伝性視神経症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.8％で5億3,000万米ドルに成長します。予測期間中に予想される成長は、革新的な治療や介入に対する需要の高まり、専門的な診断サービスに対するニーズの高まり、視神経疾患に対する認識の高まりと早期発見、LHONの新規治療に対する関心の高まり、製品設計と品質改善における継続的な進歩に起因すると考えられます。この期間に予想される主な動向には、標的治療の開発、遺伝子検査技術の進歩、外科的・薬理学的治療法の進歩、遺伝子治療技術の革新、遺伝子治療応用の広範な拡大などがあります。

緑内障と視神経炎の罹患率の増加は、今後数年間のLeber遺伝性視神経症（LHON）治療市場の成長に大きく寄与すると予想されます。緑内障と視神経炎は、視神経に障害をもたらす眼疾患であり、緑内障は一般的に眼圧の上昇によって引き起こされ、視神経炎は一般的に自己免疫疾患に関連した炎症と関連しており、どちらも視力低下につながる可能性があります。これらの疾患が増加しているのは、人口の高齢化と診断技術の進歩によるところが大きいです。世界人口の高齢化が進むにつれ、眼圧上昇による視神経障害を特徴とする緑内障の発症リスクは著しく上昇します。緑内障と視神経炎はいずれも視神経変性を伴い、LHONに類似した疾患です。これらの疾患の有病率の上昇に伴い、視神経障害をターゲットとした治療法に関する調査や啓蒙活動が活発化しており、LHONの治療オプションの進展にも貢献しています。例えば、2024年10月、米国疾病予防管理センターは、現在300万人以上の米国人が緑内障に罹患しており、高齢化により2050年までにその数は2倍の630万人になると予想されると報告しました。この動向は、LHON治療ソリューションの需要拡大に寄与しています。

標的治療の進歩も、視覚関連疾患の遺伝子治療における技術革新を促進する上で重要な役割を果たしています。LHON治療市場の主要企業は、治療効果の向上、ミトコンドリア機能の回復、LHONの遺伝的基盤への対処を目的として、遺伝子治療臨床試験を含む最先端の治療法の開発を優先しています。これらの遺伝子治療イニシアチブは、ND4などの欠陥のあるミトコンドリア遺伝子の機能的コピーを提供することにより、視力を回復させるように設計されています。これらの治療は、前臨床試験から第1相、第2相、第3相臨床試験までの厳しい段階を経て、規制当局の承認を得ることができます。例えば、2023年8月、中国を拠点とする遺伝子治療会社Neurophth Therapeutics社は、中国と米国でND1-LHON治療の第I/II相臨床試験を開始しました。この臨床試験は、米国FDAと中国NMPAの両方から承認を受けたもので、NFS-02療法の安全性、忍容性、有効性を評価することを目的としています。最初の患者への投与は、同社の世界開発戦略における重要なマイルストーンであり、同社は引き続き患者募集を加速させ、他の希少疾患やアンメット・メディカル・ニーズに対するさらなる遺伝子治療ソリューションを探求していきます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のレーバー遺伝性視神経症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のレーバー遺伝性視神経症治療市場：成長率分析
• 世界のレーバー遺伝性視神経症治療市場の実績：規模と成長、2019年～2024年
• 世界のレーバー遺伝性視神経症治療市場の予測：規模と成長、2024年～2029年、2034年
• 世界のレーバー遺伝性視神経症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のレーバー遺伝性視神経症治療市場：治療別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 医薬品
• 幹細胞療法
• 遺伝子治療
• 遺伝カウンセリング
• 世界のレーバー遺伝性視神経症治療市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 筋肉内
• 経口
• その他の投与経路
• 世界のレーバー遺伝性視神経症治療市場：診断別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 分子遺伝学的検査
• 磁気共鳴画像法（MRI）
• 血液検査
• その他の診断
• 世界のレーバー遺伝性視神経症治療市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のレーバー遺伝性視神経症治療市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• クリニック
• 病院
• その他のエンドユーザー
• 世界のレーバー遺伝性視神経症治療市場、医薬品の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• イデベノン
• 抗酸化物質
• ミトコンドリア標的療法
• 神経保護剤
• 世界のレーバー遺伝性視神経症治療市場、幹細胞療法の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 自家幹細胞療法
• 同種幹細胞療法
• 人工多能性幹細胞（iPSC）療法
• 世界のレーバー遺伝性視神経症治療市場、遺伝子治療の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• アデノ随伴ウイルス（AAV）を介した治療
• ミトコンドリア遺伝子編集
• RNAベースの治療法
• 世界のレーバー遺伝性視神経症治療市場、遺伝カウンセリングの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• キャリアスクリーニング
• 予測テスト
• 家族リスク評価
• 発症前遺伝カウンセリング

第7章 地域別・国別分析

• 世界のレーバー遺伝性視神経症治療市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のレーバー遺伝性視神経症治療市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• レーバー遺伝性視神経症治療市場：競合情勢
• レーバー遺伝性視神経症治療市場：企業プロファイル
  • UPMC Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Mayo Foundation for Medical Education and Research Overview, Products and Services, Strategy and Financial Analysis
  • Cleveland Clinic Foundation Overview, Products and Services, Strategy and Financial Analysis
  • The Children's Hospital of Philadelphia Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Chiesi Farmaceutici S.p.A.
• Medicover Hospitals
• Harvard Medical School
• BridgeBio Pharma Inc.
• Neurophth Therapeutics Co. Ltd.
• PreventionGenetics
• Stealth BioTherapeutics Corp.
• Genethon
• Reneo Pharmaceuticals Inc.
• GenSight Biologics S.A.
• Eye Stem Cell Center
• Khondrion B.V.
• Ixchel Pharma Inc.
• Abliva AB
• Mitotech S.A.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• レーバー遺伝性視神経症治療市場2029年：新たな機会を提供する国
• レーバー遺伝性視神経症治療市場2029年：新たな機会を提供するセグメント
• レーバー遺伝性視神経症治療市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Leber hereditary optic neuropathy (LHON) treatment involves medical strategies designed to manage or alleviate the effects of LHON, a rare genetic condition that leads to sudden vision loss, most often in young adults. This disorder is caused by mutations in mitochondrial DNA, which result in degeneration of the optic nerve due to impaired function of retinal ganglion cells, leading to significant vision impairment.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Primary treatment options for LHON include medication, stem cell therapy, gene therapy, and genetic counseling. Medications help manage symptoms by addressing underlying causes and may be administered in forms such as tablets or injections to reduce inflammation, support nerve health, and treat conditions associated with LHON. These treatments are delivered through various routes, including intramuscular, oral, and others. Diagnosis is made using a range of methods such as molecular genetic testing, magnetic resonance imaging (MRI), and blood tests. Treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a variety of end-users, including clinics, hospitals, and other healthcare facilities.

The leber hereditary optic neuropathy treatment market research report is one of a series of new reports from The Business Research Company that provides leber hereditary optic neuropathy treatment market statistics, including the leber hereditary optic neuropathy treatment industry global market size, regional shares, competitors with the leber hereditary optic neuropathy treatment market share, detailed leber hereditary optic neuropathy treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the leber hereditary optic neuropathy treatment industry. This leber hereditary optic neuropathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The leber hereditary optic neuropathy treatment market size has grown strongly in recent years. It will grow from $0.36 billion in 2024 to $0.39 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the rising prevalence of Leber hereditary optic neuropathy, an aging population, an increasing incidence of diabetes, growing demand for cell-free DNA in maternal plasma testing, and increased investment in the healthcare sector.

The leber hereditary optic neuropathy treatment market size is expected to see strong growth in the next few years. It will grow to $0.53 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The anticipated growth in the forecast period can be attributed to the rising demand for innovative therapies and interventions, increasing need for specialized diagnostic services, greater awareness and early detection of optic neuropathies, growing interest in novel treatments for LHON, and ongoing advancements in product design and quality improvement. Key trends expected during this period include the development of targeted therapies, progress in genetic testing technologies, advancements in both surgical and pharmacological treatment options, innovations in gene therapy techniques, and the broader expansion of gene therapy applications.

The increasing incidence of glaucomas and optic neuritis is expected to contribute significantly to the growth of the Leber hereditary optic neuropathy (LHON) treatment market in the coming years. Glaucoma and optic neuritis are eye disorders that result in damage to the optic nerve, with glaucoma commonly caused by elevated intraocular pressure, and optic neuritis typically associated with inflammation linked to autoimmune conditions, both potentially leading to vision loss. The growing occurrence of these conditions is largely attributed to an aging population and advancements in diagnostic technologies. As the global population continues to age, the risk of developing glaucoma characterized by optic nerve damage due to increased intraocular pressure rises markedly. Both glaucoma and optic neuritis involve optic nerve degeneration, a condition similar to LHON. With the rising prevalence of these disorders, research and awareness efforts are becoming more focused on therapies targeting optic nerve damage, which also aids in advancing treatment options for LHON. For example, in October 2024, the Centers for Disease Control and Prevention reported that over 3 million Americans currently suffer from glaucoma, a number expected to double to 6.3 million by 2050 due to the aging population. This trend is contributing to the growing demand for LHON treatment solutions.

Advancements in targeted therapies are also playing a key role in driving innovation in the genetic treatment of vision-related disorders. Leading companies in the LHON treatment market are prioritizing the development of cutting-edge treatments, including gene therapy clinical trials, with the aim of enhancing therapeutic efficacy, restoring mitochondrial function, and addressing the genetic basis of LHON. These gene therapy initiatives are designed to restore vision by delivering functional copies of defective mitochondrial genes, such as ND4. These treatments undergo rigorous phases, from preclinical studies through to phase 1, 2, and 3 clinical trials, before regulatory approval can be granted. For instance, in August 2023, Neurophth Therapeutics, a gene therapy company based in China, launched a Phase I/II clinical trial for ND1-LHON treatment in China and the United States. This trial, which received approval from both the U.S. FDA and China's NMPA, aims to assess the safety, tolerability, and effectiveness of its NFS-02 therapy. The dosing of the first patient marked a significant milestone in the company's global development strategy, as it continues to accelerate patient recruitment and explore further gene therapy solutions for other rare and unmet medical needs.

In July 2023, Chiesi Farmaceutici S.p.A., an Italy-based company specializing in research-driven healthcare solutions, acquired the Raxone/idebenone business from Santhera Pharmaceuticals for an undisclosed sum. This acquisition is intended to enhance Chiesi's rare disease portfolio and reinforce its position in the treatment of Leber hereditary optic neuropathy (LHON). Santhera Pharmaceuticals, based in Switzerland, focuses on developing treatments for LHON.

Major players in the leber hereditary optic neuropathy treatment market are UPMC, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic Foundation, The Children's Hospital of Philadelphia, Chiesi Farmaceutici S.p.A., Medicover Hospitals, Harvard Medical School, BridgeBio Pharma Inc., Neurophth Therapeutics Co. Ltd., PreventionGenetics, Stealth BioTherapeutics Corp., Genethon, Reneo Pharmaceuticals Inc., GenSight Biologics S.A., Eye Stem Cell Center, Khondrion B.V., Ixchel Pharma Inc., Abliva AB, Mitotech S.A.

North America was the largest region in the leber hereditary optic neuropathy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in leber hereditary optic neuropathy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the leber hereditary optic neuropathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The leber hereditary optic neuropathy treatment market consists of revenues earned by entities providing services such as mitochondrial support therapies, diagnostic testing, and vision rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The leber hereditary optic neuropathy (LHON) treatment market also includes sales of antioxidants and supportive care medications aimed at managing vision loss and disease progression. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Leber Hereditary Optic Neuropathy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on leber hereditary optic neuropathy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for leber hereditary optic neuropathy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The leber hereditary optic neuropathy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medication; Stem Cell Therapy; Gene Therapy; Genetic Counseling
• 2) By Route Of Administration: Intramuscular; Oral; Other Routes Of Administration
• 3) By Diagnosis: Molecular Genetic Testing; Magnetic Resonance Imaging (MRI); Blood tests; Other Diagnosis
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 5) By End-Users: Clinic; Hospital; Other End-Users
• Subsegments:
• 1) By Medication: Idebenone; Antioxidants; Mitochondrial-Targeted Therapies; Neuroprotective Agents
• 2) By Stem Cell Therapy: Autologous Stem Cell Therapy; Allogeneic Stem Cell Therapy; Induced Pluripotent Stem Cell (iPSC) Therapy
• 3) By Gene Therapy: Adeno-Associated Virus (AAV)-Mediated Therapy; Mitochondrial Gene Editing; RNA-Based Therapies
• 4) By Genetic Counseling: Carrier Screening; Predictive Testing; Family Risk Assessment; Pre-Symptomatic Genetic Counseling
• Companies Mentioned: UPMC; Astellas Pharma Inc.; Mayo Foundation for Medical Education and Research; Cleveland Clinic Foundation; The Children's Hospital of Philadelphia
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Leber Hereditary Optic Neuropathy Treatment Market Characteristics

3. Leber Hereditary Optic Neuropathy Treatment Market Trends And Strategies

4. Leber Hereditary Optic Neuropathy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Leber Hereditary Optic Neuropathy Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Leber Hereditary Optic Neuropathy Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Leber Hereditary Optic Neuropathy Treatment Market Growth Rate Analysis
• 5.4. Global Leber Hereditary Optic Neuropathy Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Leber Hereditary Optic Neuropathy Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Leber Hereditary Optic Neuropathy Treatment Total Addressable Market (TAM)

6. Leber Hereditary Optic Neuropathy Treatment Market Segmentation

• 6.1. Global Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Stem Cell Therapy
• Gene Therapy
• Genetic Counseling
• 6.2. Global Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intramuscular
• Oral
• Other Routes Of Administration
• 6.3. Global Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Molecular Genetic Testing
• Magnetic Resonance Imaging (MRI)
• Blood tests
• Other Diagnosis
• 6.4. Global Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinic
• Hospital
• Other End-Users
• 6.6. Global Leber Hereditary Optic Neuropathy Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idebenone
• Antioxidants
• Mitochondrial-Targeted Therapies
• Neuroprotective Agents
• 6.7. Global Leber Hereditary Optic Neuropathy Treatment Market, Sub-Segmentation Of Stem Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell Therapy
• Allogeneic Stem Cell Therapy
• Induced Pluripotent Stem Cell (iPSC) Therapy
• 6.8. Global Leber Hereditary Optic Neuropathy Treatment Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adeno-Associated Virus (AAV)-Mediated Therapy
• Mitochondrial Gene Editing
• RNA-Based Therapies
• 6.9. Global Leber Hereditary Optic Neuropathy Treatment Market, Sub-Segmentation Of Genetic Counseling, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Carrier Screening
• Predictive Testing
• Family Risk Assessment
• Pre-Symptomatic Genetic Counseling

7. Leber Hereditary Optic Neuropathy Treatment Market Regional And Country Analysis

• 7.1. Global Leber Hereditary Optic Neuropathy Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Leber Hereditary Optic Neuropathy Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Leber Hereditary Optic Neuropathy Treatment Market

• 8.1. Asia-Pacific Leber Hereditary Optic Neuropathy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Leber Hereditary Optic Neuropathy Treatment Market

• 9.1. China Leber Hereditary Optic Neuropathy Treatment Market Overview
• 9.2. China Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Leber Hereditary Optic Neuropathy Treatment Market

• 10.1. India Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Leber Hereditary Optic Neuropathy Treatment Market

• 11.1. Japan Leber Hereditary Optic Neuropathy Treatment Market Overview
• 11.2. Japan Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Leber Hereditary Optic Neuropathy Treatment Market

• 12.1. Australia Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Leber Hereditary Optic Neuropathy Treatment Market

• 13.1. Indonesia Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Leber Hereditary Optic Neuropathy Treatment Market

• 14.1. South Korea Leber Hereditary Optic Neuropathy Treatment Market Overview
• 14.2. South Korea Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Leber Hereditary Optic Neuropathy Treatment Market

• 15.1. Western Europe Leber Hereditary Optic Neuropathy Treatment Market Overview
• 15.2. Western Europe Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Leber Hereditary Optic Neuropathy Treatment Market

• 16.1. UK Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Leber Hereditary Optic Neuropathy Treatment Market

• 17.1. Germany Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Leber Hereditary Optic Neuropathy Treatment Market

• 18.1. France Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Leber Hereditary Optic Neuropathy Treatment Market

• 19.1. Italy Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Leber Hereditary Optic Neuropathy Treatment Market

• 20.1. Spain Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Leber Hereditary Optic Neuropathy Treatment Market

• 21.1. Eastern Europe Leber Hereditary Optic Neuropathy Treatment Market Overview
• 21.2. Eastern Europe Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Leber Hereditary Optic Neuropathy Treatment Market

• 22.1. Russia Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Leber Hereditary Optic Neuropathy Treatment Market

• 23.1. North America Leber Hereditary Optic Neuropathy Treatment Market Overview
• 23.2. North America Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Leber Hereditary Optic Neuropathy Treatment Market

• 24.1. USA Leber Hereditary Optic Neuropathy Treatment Market Overview
• 24.2. USA Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Leber Hereditary Optic Neuropathy Treatment Market

• 25.1. Canada Leber Hereditary Optic Neuropathy Treatment Market Overview
• 25.2. Canada Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Leber Hereditary Optic Neuropathy Treatment Market

• 26.1. South America Leber Hereditary Optic Neuropathy Treatment Market Overview
• 26.2. South America Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Leber Hereditary Optic Neuropathy Treatment Market

• 27.1. Brazil Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Leber Hereditary Optic Neuropathy Treatment Market

• 28.1. Middle East Leber Hereditary Optic Neuropathy Treatment Market Overview
• 28.2. Middle East Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Leber Hereditary Optic Neuropathy Treatment Market

• 29.1. Africa Leber Hereditary Optic Neuropathy Treatment Market Overview
• 29.2. Africa Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Leber Hereditary Optic Neuropathy Treatment Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Leber Hereditary Optic Neuropathy Treatment Market Competitive Landscape And Company Profiles

• 30.1. Leber Hereditary Optic Neuropathy Treatment Market Competitive Landscape
• 30.2. Leber Hereditary Optic Neuropathy Treatment Market Company Profiles
  • 30.2.1. UPMC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Mayo Foundation for Medical Education and Research Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Cleveland Clinic Foundation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. The Children's Hospital of Philadelphia Overview, Products and Services, Strategy and Financial Analysis

31. Leber Hereditary Optic Neuropathy Treatment Market Other Major And Innovative Companies

• 31.1. Chiesi Farmaceutici S.p.A.
• 31.2. Medicover Hospitals
• 31.3. Harvard Medical School
• 31.4. BridgeBio Pharma Inc.
• 31.5. Neurophth Therapeutics Co. Ltd.
• 31.6. PreventionGenetics
• 31.7. Stealth BioTherapeutics Corp.
• 31.8. Genethon
• 31.9. Reneo Pharmaceuticals Inc.
• 31.10. GenSight Biologics S.A.
• 31.11. Eye Stem Cell Center
• 31.12. Khondrion B.V.
• 31.13. Ixchel Pharma Inc.
• 31.14. Abliva AB
• 31.15. Mitotech S.A.

32. Global Leber Hereditary Optic Neuropathy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Leber Hereditary Optic Neuropathy Treatment Market

34. Recent Developments In The Leber Hereditary Optic Neuropathy Treatment Market

35. Leber Hereditary Optic Neuropathy Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Leber Hereditary Optic Neuropathy Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Leber Hereditary Optic Neuropathy Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Leber Hereditary Optic Neuropathy Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34890_Leber_Hereditary_Optic_Neuropathy_Treatment_GMR_2025